$ELUT News

Last published 6d ago

6d agoELUTElutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through LaunchGlobeNewswireInfection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection
6d agoELUTElutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through LaunchGlobeNewswireElutia Reports Q3 2026 Results: As Plastic Surgeons Cite Infection Risk at National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through...
6d agoELUTELUTIA INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2w agoELUTElutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswireGAITHERSBURG, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its
2mo agoELUTElutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15thGlobeNewswireGAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills,
2mo agoELUTElutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireGAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills,
2mo agoELUTCellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.GlobeNewswireROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. ("Cellution Biologics" or the "Company"), a biologics company focused on developing, manufacturing and commercializing advanced
2mo agoELUTElutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial LaunchGlobeNewswireDeal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the
3mo agoELUTElutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 ResultsGlobeNewswireFunded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of
3mo agoELUTElutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery MarketGlobeNewswire$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41xPreserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix
3mo agoELUTElutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026GlobeNewswireGAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its
3mo agoELUTElutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x LaunchGlobeNewswireTransaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital to advance NXT-41x
5mo agoELUTElutia to Present at Planet MicroCap Showcase 2026 on June 17thGlobeNewswireGAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief
5mo agoCNXU ELUT PCRX SNN+1A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingGlobeNewswireFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary —
5mo agoELUTElutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireGAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards
6mo agoELUTElutia Q1 2026 Financial Results CallELUTIA INCEarnings Call TranscriptsThank you for standing by and welcome to ELUSHA's first quarter 2026 earnings conference call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer
6mo agoELUTElutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery MarketGlobeNewswireNXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparationsBrought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scaleChief Commercial
6mo agoELUTElutia to Present at the 16th Annual LD Micro Invitational on May 18thGlobeNewswireGAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive
6mo agoACRX ANIK AXGN BEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
6mo agoELUTElutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026GlobeNewswireGAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026
8mo agoELUTElutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireGAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity
8mo agoELUTElutia Regains Compliance with Nasdaq Listing RequirementsGlobeNewswireGAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice
8mo agoELUTElutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery MarketGlobeNewswireGAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete
8mo agoELUTElutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026GlobeNewswireGAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025
8mo agoELUTWhere Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™GlobeNewswireGAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great
10mo agoELUTElutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x MilestonesGlobeNewswireFourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc.
10mo agoELUTElutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive SurgeryGlobeNewswireCompany to present Tuesday, January 13th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix
1y agoELUTElutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x DevelopmentGlobeNewswire- Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET /
1y agoELUTElutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewswireGAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025
1y agoELUTElutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21GlobeNewswireGAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer,
1y agoELUTElutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of DirectorsGlobeNewswireIndustry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"),
1y agoBSX ELUTElutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 MillionGlobeNewswire- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025
1y agoELUTElutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of ReoperationGlobeNewswire- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc.
1y agoBSX ELUTElutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 MillionGlobeNewswire- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual
1y agoELUTElutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology ExchangeGlobeNewswireGAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the
1y agoELUTElutia to Participate in Upcoming Investor ConferencesGlobeNewswireGAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer,
1y agoELUTElutia Inc. (ELUT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoELUTElutia Delivers Robust Growth on the Strength of EluPro™ Market AdoptionGlobeNewswireEluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025
1y agoELUTElutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025GlobeNewswireGAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025
1y agoELUTDr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator AwardGlobeNewswireGAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief
1y agoELUTNew Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable DevicesGlobeNewswire— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025
1y agoELUTElutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence AwardsGlobeNewswireRecognition highlights EluPro™ Antibiotic-Eluting BioEnvelope's impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE
1y agoELUTElutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing MethodGlobeNewswireSILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article
1y agoELUTElutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ SalesGlobeNewswire- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or
1y agoELUTElutia Transitions to Direct Distribution of Its Cardiovascular Product PortfolioGlobeNewswireMove expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix
1y agoELUTElutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025GlobeNewswireSILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025
1y agoELUTElutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29GlobeNewswireSILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia's Chief
1y agoELUTElutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical PracticeGlobeNewswire— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE
1y agoELUTElutia Confirms No Material Impact from Global TariffsGlobeNewswireSILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has
1y agoELUTEluPro™ Named as 2025 Edison Award WinnerGlobeNewswireInnovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category SILVER SPRING, Md., April 04, 2025 (GLOBE